Glenmark UpBEAT As Tech Yields First Oncology Lead
This article was originally published in PharmAsia News
Glenmark has scored a significant win in its search for potent candidates to treat cancers. Its BEAT platform technology has successfully combined two antibodies that could potentially be superior to existing therapies.
You may also be interested in...
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.